(Q38083041)

28 August 2017

Immunotherapy of multiple sclerosis: the state of the art. (English)

1 reference

28 August 2017

0 references

1 reference

Dimitrios Karussis

1

1 reference

28 August 2017

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

27

1 reference

28 August 2017

2

1 reference

28 August 2017

113-148

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-013-0011-z

28 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

T cells responsive to myelin basic protein in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A review of T-cell receptors in multiple sclerosis: clonal expansion and persistence of human T-cells specific for an immunodominant myelin basic protein peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Memory CD4+CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Th17 cells in human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Adhesion of cerebral endothelial cells to lymphocytes from patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

B lymphocytes--chief players and therapeutic targets in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

The B cell response in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intravenous methylprednisolone for multiple sclerosis in relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Therapeutic plasma exchange: an update from the Canadian Apheresis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Plasmapheresis for neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Beneficial plasma exchange response in central nervous system inflammatory demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

The rescue effect of plasma exchange for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon-beta mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Long-term follow-up of clinical trials of multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon beta-1a in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

The efficacy of azathioprine in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mechanism of action of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Methotrexate--how does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A systematic review of oral methotrexate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intrathecal methotrexate treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Cladribine: mode of action and implications for treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mycophenolate mofetil in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A trial of antilymphocyte globulin in the treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

New concepts on progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intrathecal effects of daclizumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

An open trial of OKT3 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Laquinimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Dimethyl fumarate for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

T cell vaccination in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

T cell vaccination in multiple sclerosis: results of a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Autologous T-cell vaccination for multiple sclerosis: a perspective on progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Antigen-driven bystander suppression after oral administration of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Current issues in the treatment of human diseases by mucosal tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Immunomodulatory properties of mesenchymal stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Mesenchymal stem cells: a new strategy for immunosuppression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Immunoregulatory function of mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

MRI--the perfect surrogate marker for multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Treatment optimization in multiple sclerosis: report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0011-Z

10.1007/S40259-013-0011-Z

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23423844